For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- With Eyes on Pricey Meds, Cost-Shaving Debate Unabated Despite Likely Tax Hike Delay
April 11, 2016
- Centralized Support Unit Needed for “Clinical Innovation Network”: JPMA’s Teshirogi
April 8, 2016
- PMDA to Set Up Hokuriku Branch to Train Asian Regulators
April 8, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for March
April 8, 2016
- MHLW Advisory Panel to Discuss Nobelpharma’s Epilepsy Drug on April 20
April 8, 2016
- NCCHD Aims to Build “Million-Person Database” on Pediatric Patients; Could Lead to Improvements in Pharmacotherapy
April 6, 2016
- Govt OKs Action Plan on Drug Resistance
April 6, 2016
- MEXT to Set Up “Shared Facilities” for Drug Discovery, Push Open Innovation
April 5, 2016
- MOF Panel Hears Expert’s Opinions on Opdivo Prices
April 5, 2016
- Key Govt Panel Kicks Off Discussions on Economic, Fiscal Policy Blueprint
April 5, 2016
- Govt Aims to Reduce Use of Antimicrobials by 33% by FY2020 as Part of Efforts to Fight Resistance
April 5, 2016
- 14-Day Prescription Limit to Be Discussed toward Next Reform: MHLW Official
April 4, 2016
- Xarelto under Review for Thrombocytopenia Risk
April 4, 2016
- Clinical Research Bill Won’t Be Enacted in Current Diet Session: LDP Health Panel Chief
March 30, 2016
- MHLW OKs AZ’s Tagrisso, Novartis’s Zykadia for Lung Cancer
March 29, 2016
- PMDA to Establish Asian Regulatory Training Center on April 1
March 29, 2016
- Panel Finalizes “No Efficacy” Decision for Lysozyme, Pronase; MHLW Issues Notifications for Ethical, OTC Products
March 28, 2016
- Drug Makers, Distributors Won’t Set Interim Targets for Mandatory Barcode Labeling, but Keep Tabs on Progress
March 25, 2016
- MHLW Officially Sets Out Plan to Draw Up New Pharma Industry Vision
March 24, 2016
- Shiozaki Hints at Delay in MHLW Report on Vaccines and Blood Product Policies
March 24, 2016
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…